University of British Columbia
Development of biomarkers for colorectal cancer : transverse colon primary tumor location and circulating tumor DNA for molecular residual disease
Abstract
dc:descriptionBiomarker development is essential for improving colorectal cancer (CRC) care. Primary tumor location is prognostic and predictive of efficacy of anti-EGFR monoclonal antibodies in metastatic CRC (mCRC). Traditionally, mCRC from transverse colon (TC) has been excluded or analyzed as right-sided (RS), resulting in limited information about TC as a unique entity and the ideal transition point for sidedness analysis. Circulating tumor DNA (ctDNA) detection is an emerging biomarker for molecular residual disease (MRD), and its detection is strongly associated with recurrence after curative treatment. However, additional validation and utility investigations are needed before incorporation into clinical practice. This thesis sought to further develop these candidate biomarkers by examining the prognostic and predictive features of TC in uncurable mCRC and the clinical optimization of a new ctDNA-MRD test in patients with CRC treated with curative intent. TC was investigated in a pooled analysis of 553 patients from two randomized trials of cetuximab in chemotherapy-refractory mCRC. TC mCRC showed no significant benefit from cetuximab versus best supportive care (BSC) for overall survival (OS) (Hazard ratio [HR], 0.63; p=0.26) and progression-free survival (PFS) (HR, 0.57; p=0.16). Among cetuximab-treated patients, TC outcomes were similar to RS (OS HR, 0.63 p=0.26; PFS HR, 0.57 p=0.16) but inferior to left-sided (OS HR, 0.42 p=0.0002; PFS HR, 0.49; p=0.001). Sidedness was not prognostic in BSC-treated patients. A new ctDNA-MRD assay was investigated in 50 patients from a prospective cohort treated with curative intent. At baseline, the assay showed a sensitivity of 82.9% for CRC detection, and neoadjuvant treatment was associated with higher rates of false negative results (Odds ratio, 15.75; p=0.0047). During the MRD evaluation window (weeks 2-8), ctDNA detection was associated with clinical recurrence (multivariate HR, 4.44; p=0.032), and assay sensitivity was 72.7%. Recurrence was anticipated by 6.4 months, with initial ctDNA detection occurring at levels <100 ppm in 63.6% and most frequently at weeks 2 (27.3%) and 4 (36.4%). In summary, TC as a biomarker has prognostic and predictive features comparable with RS in mCRC, and the detection of MRD with a new ctDNA assay is prognostic for CRC recurrence post-curative treatment.
Degree
thesis:*- Name thesis:degree_name
- Master of Science - MSc
- Level thesis:degree_level
- master's
- Discipline thesis:degree_discipline
- Experimental Medicine
- Grantor dc:publisher
- University of British Columbia
- Year dc:date
- 2024
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Solar Vasconcelos, Joao Paulo
- Contributors dc:contributor
-
- Loree, Jonathan M.
Rights
dc:rights- Statement dc:rights
-
- Attribution-NonCommercial-NoDerivatives 4.0 International
- Language dc:language
- eng
Identifiers
dc:identifier.*- Handle dc:identifier
- http://hdl.handle.net/2429/89438